These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1872309)

  • 61. Insulin use in NIDDM.
    Genuth S
    Diabetes Care; 1990 Dec; 13(12):1240-64. PubMed ID: 2276309
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes.
    Ceriello A; Johns D; Widel M; Eckland DJ; Gilmore KJ; Tan MH
    Diabetes Care; 2005 Feb; 28(2):266-72. PubMed ID: 15677777
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Morning or bedtime NPH insulin combined with sulfonylurea in treatment of NIDDM.
    Groop LC; Widén E; Ekstrand A; Saloranta C; Franssila-Kallunki A; Schalin-Jäntti C; Eriksson JG
    Diabetes Care; 1992 Jul; 15(7):831-4. PubMed ID: 1516500
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sulfonylurea-metformin-combination versus sulfonylurea-insulin-combination in secondary failures of sulfonylurea monotherapy. Results of a prospective randomized study in 50 patients.
    Klein W
    Diabete Metab; 1991 May; 17(1 Pt 2):235-40. PubMed ID: 1936483
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus.
    Sonnenberg GE; Garg DC; Weidler DJ; Dixon RM; Jaber LA; Bowen AJ; DeChemey GS; Mullican WS; Stonesifer LD
    Ann Pharmacother; 1997 Jun; 31(6):671-6. PubMed ID: 9184703
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Selective unresponsiveness of pancreatic beta-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM.
    Karam JH; Sanz N; Salamon E; Nolte MS
    Diabetes; 1986 Dec; 35(12):1314-20. PubMed ID: 3533680
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Combining insulin and sulfonylurea. A therapeutic option for type II diabetes.
    Riddle MC
    Postgrad Med; 1992 Aug; 92(2):89-90, 95-6, 99-102. PubMed ID: 1495886
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The impact of sulfonylureas on hepatic glucose metabolism in type II diabetics.
    Kolterman OG
    Diabetes Metab Rev; 1987 Apr; 3(2):399-414. PubMed ID: 3552528
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Combined insulin and oral sulfonylureas--how sweet it isn't!
    Ponte CD
    DICP; 1990 Dec; 24(12):1234-5. PubMed ID: 2089839
    [No Abstract]   [Full Text] [Related]  

  • 70. Rational use of sulfonylureas.
    Davidson MB
    Postgrad Med; 1992 Aug; 92(2):69-70, 73-6, 79-85. PubMed ID: 1495885
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Combination of insulin and sulfonylureas: a literature review.
    Halimi S; Corticelli P; Benhamou PY
    Am J Med; 1991 Jun; 90(6A):83S-86S. PubMed ID: 1872311
    [No Abstract]   [Full Text] [Related]  

  • 72. Treatment strategies for patients with non-insulin-dependent diabetes mellitus.
    Boden G
    Am J Med; 1985 Aug; 79(2B):23-6. PubMed ID: 2994471
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The treatment of NIDDM in the decade of the 90s.
    Krall LP
    Diabetes Res Clin Pract; 1991; 14 Suppl 2():S15-9. PubMed ID: 1794261
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Determining the most appropriate treatment for patients with non-insulin-dependent diabetes mellitus.
    Cooppan R
    Metabolism; 1987 Feb; 36(2 Suppl 1):17-21. PubMed ID: 3543617
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents.
    Pitocco D; Valle D; Rossi A; Gentilella R
    J Endocrinol Invest; 2008 Apr; 31(4):371-9. PubMed ID: 18475058
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Rationale for the association of sulfonylurea and insulin.
    Del Prato S
    Am J Med; 1991 Jun; 90(6A):77S-82S. PubMed ID: 1872309
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Type II diabetic subjects with secondary failure: treatment with prebreakfast mixed ultralente and regular insulin with a sulfonylurea.
    Kabadi UM; Kabadi MU
    J Fam Pract; 1991 Oct; 33(4):349-53. PubMed ID: 1919450
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Combined insulin-sulfonylurea therapy in treatment of NIDDM.
    Groop LC; Groop PH; Stenman S
    Diabetes Care; 1990 Aug; 13 Suppl 3():47-52. PubMed ID: 2209344
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hepatic sensitivity to insulin: effects of sulfonylurea drugs.
    Del Prato S; Vigili de Kreutzenberg S; Riccio A; Tiengo A
    Am J Med; 1991 Jun; 90(6A):29S-36S. PubMed ID: 1872301
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Combination insulin-sulfonylurea therapy.
    Lebovitz HE; Pasmantier R
    Diabetes Care; 1990 Jun; 13(6):667-75. PubMed ID: 2192850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.